Film-coated immediate-release tablets containing capecitabine at 150 mg and 500 mg dose strengths are manufactured by wet granulation, compression, and aqueous film coating. The intragranular fraction contains capecitabine, lactose monohydrate, microcrystalline cellulose, and croscarmellose sodium; hypromellose is added as a binder solution in purified water. Magnesium stearate is added in the final blending step. A common bulk formulation is maintained across strengths, with color-differentiating coating suspensions containing titanium dioxide and iron oxides. In a 500 mg core with a total core mass near 1000 mg, the drug load approaches 50%; a 150 mg core may be adjusted to a lower fill mass while retaining the same granule composition. The granulation endpoint is controlled by impeller torque and product temperature in a high-shear granulator. Wet mass is transferred to a fluid-bed dryer and dried until loss-on-drying reaches the range defined in the approved dossier, typically below 3.0% for this carbamate prodrug. Dried granules are milled through a 1.0 mm or 1.2 mm screen with a cone mill. Extragranular croscarmellose sodium is added as a 1:1 intragranular/extragranular disintegrant split, followed by magnesium stearate for a short final blend to avoid excessive overlubrication. Compression is run on a rotary tablet press with precompression force adjusted to reduce capping. The core is film-coated in a perforated pan with an aqueous hypromellose-based coating suspension; spray rate and product bed temperature are set to prevent overwetting. Release testing follows the compendial framework: assay and related substances by HPLC, dissolution by USP <711>, uniformity of dosage units by USP <905>, disintegration by USP <701>, and water content by USP <921>. Elemental impurities are controlled under ICH Q3D. The terminal dosage form is a round, biconvex, film-coated tablet intended for oral administration; tablet appearance and mass are controlled under 21 CFR 211 and ICH Q6A specifications.

What Limits Fill Weight Uniformity in Capecitabine Capsule Operations?

For hard gelatin or HPMC capsules containing capecitabine granules, fill weight uniformity is governed by granule bulk density, particle size distribution, and flow. A 150 mg dose in a size 0 capsule may require granulated material because direct filling of a low-density API blend leads to insufficient fill mass within the available body volume. Tapped density of the milled granule fraction is measured according to USP <616>; values are used to calculate maximum fill mass. Encapsulation is performed on a continuous-motion machine equipped with pellet dosing discs or paddle/tamping pin stations. The process is set to target a fill weight range with individual capsule mass variation controlled by USP <905>. Low-dose strengths may require ordered preblending with lactose or microcrystalline cellulose before granulation to reduce segregation during hopper discharge. Excipient compatibility is reviewed for hard gelatin capsules because moisture exchange from the shell can plasticize the granule; HPMC shells may be selected where lower moisture transfer is required. Capsule-specific product release uses assay, related substances, and dissolution according to the capsule monograph where present, or ICH Q6A where no individual pharmacopeial monograph exists. The final product is an oral capsule intended for clinical trial supply or institutional dose preparation, with terminal packaging in induction-sealed HDPE bottles containing desiccant where long-term stability data show humidity sensitivity.

High-shear wet granulation is used to produce capecitabine granules as an intermediate for tablet compression, capsule filling, or sachet packaging. The granulation fluid is prepared by dissolving hypromellose in purified water at 3% to 5% w/w; the fluid is sprayed or poured into a preblend of capecitabine, lactose monohydrate, microcrystalline cellulose, and intragranular croscarmellose sodium. Impeller speed and chopper speed are selected to produce a dough mass within 5 to 8 minutes, with endpoint determined by torque increase and visual mass consistency. Overgranulation is avoided because excessive binder hydration can reduce granule porosity and slow dissolution. The wet mass is dried in a fluid-bed dryer with product temperature maintained below 60°C; after drying, loss-on-drying is measured by USP <731> and controlled to the range established in the approved dossier. Dried granules are sized through a 1.0 mm or 1.5 mm conical mill; the retained fraction is recycled only if the particle size distribution remains within process capability. A second granulation route, roller compaction, may be used for dry granulation when moisture exposure must be minimized. Granule flow is characterized by USP <1174>; the final granule blend is filled into bulk containers or compressed into tablets. The terminal intermediate granular product may also be filled into sachets for oral administration after dose adjustment. In-process controls include granule particle size by sieve analysis, bulk/tapped density, and blend uniformity using near-infrared spectroscopy where validated.

When Direct Compression Replaces Roller Compaction in Capecitabine Blends

Direct compression of capecitabine is constrained by poor flow and high dose. At drug loads above 50% of total core weight, direct compression failure modes include segregation during hopper discharge, tablet weight variation, and capping due to low compactibility. Roller compaction is preferred because it densifies the blend, improves flow, and reduces dust. If direct compression is attempted, the API fraction must be supported by co-processed excipients such as microcrystalline cellulose-lactose compacts and a flow agent such as colloidal silicon dioxide at 0.1% to 0.5% w/w. Lubrication with magnesium stearate is limited to 0.5% to 1.0% w/w with a blending time not exceeding 5 minutes; overlubrication can retard dissolution. Blend flow is measured by USP <1174>; a flow function coefficient below 4.0 indicates cohesive behavior requiring force-controlled feeding. Tablets are compressed on a rotary press with precompression. In-process controls under 21 CFR 211.110 include tablet mass, hardness, thickness, and disintegration. The terminal dosage form is a film-coated tablet produced by dry granulation, not direct compression, where roller compaction is integrated as the preferred densification step. The direct compression option remains a development-scale alternative only when specific lots demonstrate sufficient flow and compressibility.

Oral Granule Sachets and Unit-Dose Compounding Controls

Capecitabine granules may be packaged into unit-dose sachets for dose titration in oncology regimens. The granule composition is identical to the tablet granulation, with the coating removed. Sachet filling requires low-humidity conditions because the carbamate prodrug is susceptible to hydrolytic degradation; packaging systems with aluminum foil barrier reduce moisture ingress. Filled sachet mass uniformity is tested by USP <905>, and sachet seal integrity is verified by vacuum leak testing. In hospital or compounding pharmacy settings, tablets are sometimes dispersed in water to prepare oral suspensions for patients with dysphagia. Compounding is performed according to USP <795> for nonsterile preparations; if capecitabine is classified as a hazardous drug on the NIOSH list, containment and surface deactivation procedures under USP <800> apply. The beyond-use date for an aqueous oral liquid prepared from tablets must be assigned according to USP <795>, commonly not exceeding 14 days under refrigeration unless stability data support a longer period. The terminal product is either a sealed granule sachet or an extemporaneously compounded oral liquid. Dose accuracy in sachet presentation is verified against the approved product license.

Injectable capecitabine is not a compendial dosage form in the European Pharmacopoeia, the United States Pharmacopeia, or the Japanese Pharmacopoeia. The molecule is developed as an oral prodrug of 5-fluorouracil, and intravenous administration is not the licensed route because the conversion enzymes and tissue exposure profile differ from direct 5-FU infusion. Development of an injectable capecitabine formulation is confined to preclinical preformulation studies. Aqueous solubility of the free base is low, and aqueous solution stability is pH-dependent due to carbamate hydrolysis. Published data for this specific configuration is limited. If an injectable presentation were developed, it would require lyophilized powder fill or a complexing agent under aseptic processing; terminal steam sterilization may be unsuitable where hydrolytic degradation is accelerated at elevated temperature. The formulation would be manufactured in an isolator or RABS under EU GMP Annex 1 and 21 CFR 210/211, with container closure integrity testing and sterility per USP <71>. Terminal product would be a sterile lyophilized powder for reconstitution, but no approved commercial product of this type exists. Comparative clinical use is addressed through injectable 5-FU, not capecitabine injection.